Literature DB >> 20728740

Is advanced renal cell carcinoma becoming a chronic disease?

James Larkin1, Martin Gore.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20728740     DOI: 10.1016/S0140-6736(10)60816-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Authors:  Wilfred D Stein; Julia Wilkerson; Sindy T Kim; Xin Huang; Robert J Motzer; Antonio Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2012-02-17       Impact factor: 12.531

2.  Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

Authors:  E Herrmann; N Marschner; M O Grimm; C H Ohlmann; U Hutzschenreuter; F Overkamp; M Groschek; K Blumenstengel; G Pühse; T Steiner
Journal:  World J Urol       Date:  2011-04-03       Impact factor: 4.226

3.  Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  EPMA J       Date:  2011-12-22       Impact factor: 6.543

4.  A unique presentation of a renal clear cell carcinoma with atypical metastases.

Authors:  F Staderini; F Cianchi; B Badii; I Skalamera; G Fiorenza; C Foppa; E Qirici; G Perigli
Journal:  Int J Surg Case Rep       Date:  2015-04-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.